16:35

Heterogeneity of NSCLC and precipitating oncogenic driver mutations

HMP Education

20:18

Understanding, preventing, and delaying EGFR resistance in the era of Osimertinib

HMP Education

20:24

Targeted treatment with EGFR TKIs: Front line options

HMP Education

32:26

NSCLC: Interactive Case-based Panel Discussion

HMP Education